Skip to content

EyePoint, Inc.

company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery

EYPT Nasdaq SEC CIK 1314102

Follow EyePoint Weekly email: filings, results, news

News

9 stories filed under EyePoint, grouped into ongoing threads

Phase

Thread · 3 stories

EyePoint: Still A Sell After Phase 3 Crash

Markets 36 d ago

EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript

Markets 37 d ago also on III AMD

EyePoint: Phase 3 Design Creates A More Valuable Durability Story

Markets 47 d ago

More coverage

EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward

Markets 28 d ago

EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown

Markets 36 d ago

EyePoint director Karen L. Zaderej buys $52,258 in stock

Markets 37 d ago

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

Markets 37 d ago

Stifel reiterates EyePoint stock Buy rating after trial miss

Markets 38 d ago 3 sources

EyePoint plummets on pivotal data for main drug

Markets 38 d ago also on AMD

Next results

NOV4

Q4 2026 results

Wednesday · estimated from the filing cadence

Profile

Headquarters: WATERTOWN, MA, United States
Sector: Technology
Industry: Laboratory Analytical Instruments
Website: psivida.com

Peers

Where this page comes from

Profile · SEC EDGAR, Wikidata

Next results · estimated from the filing cadence (SEC EDGAR)

News · 9 stories clustered from the RSS aggregator